5-Isopropyl-3-phenylisoxazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Isopropyl-3-phenylisoxazole
• 英文别名: 3-Phenyl-5-propan-2-yl-1,2-oxazole
• 化学式: C₁₂H₁₃NO
• 分子量: 187.241
• InChiKey: QLDQUTIKZDTKRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-Isopropyl-3-phenylisoxazole 、 三氟甲烷磺酸甲酯 以 二氯甲烷 为溶剂， 反应 18.0h， 以79%的产率得到2-methyl-5-(1-methylethyl)-3-phenylisoxazolium trifluoromethanesulfonate
  参考文献：
  名称：

  手性铱催化剂对异恶唑鎓三氟甲磺酸酯的不对称加氢

  摘要：

  在H 2存在下，铱催化剂[IrCl（cod）] 2-膦-I 2（cod = 1,5-环辛二烯）选择性地将三氟甲磺酸异恶唑鎓还原为异恶唑啉或异恶唑烷。当使用旋光性膦-恶唑啉配体时，铱催化的氢化反应以高至良好的对映选择性进行。将3-取代的5-芳基异恶唑鎓盐转化为4-异恶唑啉，对映体比例高达95：5（er）。手性顺式-异唑烷类化合物的最高获得时间为89:11，没有形成反式异构体，当底物在5位上具有伯烷基取代基时。机理研究表明，氢化铱（III）物种倾向于将其氢化物传递到异恶唑环的C5原子上。氢化物侵蚀导致3-异恶唑啉中间体形成手性异恶唑烷。同时，在4-异恶唑啉的选择性形成中，5-芳基取代基的空间位阻可能会阻碍C5原子处的氢化物攻击。

  DOI：

  10.1002/chem.201600732
• 作为产物：
  描述：

  苯甲腈 N-氧化物 在 2,2,6,6-tetramethylpiperidinyl-lithium 、 仲丁基锂 、 sodium carbonate 、 二异丙胺 作用下， 以 甲醇 、 环己烷 、 水 、 正戊烷 为溶剂， 反应 4.0h， 生成 5-Isopropyl-3-phenylisoxazole
  参考文献：
  名称：

  Regioselective synthesis and side-chain metallation and elaboration of 3-aryl-5-alkylisoxazoles

  摘要：

  A number of 3-aryl-5-alkylisoxazoles have been synthesized in high yields by reacting arylnitrile oxides with free enolate ions regioselectively obtained by metallation of various alkyl methyl ketones with LDA in THF at -78degreesC followed by dehydration. Investigations concerning regioselective side-chain metallation and elaboration of one of them (3-phenyl-5-ethylisoxazole) have also been carried out. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)00125-4

文献信息

• Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
  申请人：Maeda Dean Y.

  公开号：US20100210593A1

  公开（公告）日：2010-08-19

  There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.

  披露了作为药物剂的吡啶和嘧啶羧酰胺化合物，合成过程以及包括吡啶和嘧啶羧酰胺化合物的药物组合物。更具体地，披露了一类CXCR2抑制剂化合物，可用于治疗各种炎症和肿瘤性疾病。
• [EN] MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI<br/>[FR] DÉRIVÉS DE MANNOSE UTILES POUR LE TRAITEMENT DE PATHOLOGIES ASSOCIÉES À E. COLI ADHÉRENTS
  申请人：ENTEROME

  公开号：WO2017021549A1

  公开（公告）日：2017-02-09

  The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO-(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X' represents OH or X and X' taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6 )-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO-(C1-C6 )-alkyl, CF3 or COCF3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.

  本发明涉及式(I)的甘露糖衍生物：其中R1代表H、CO-(C1-C6)-烷基或CO-烷基芳基，Y代表单键、CH2、O、NR3、S，A代表O、NH或S，X代表H，X'代表OH或X和X'与它们相连的碳原子形成CO基团，R2代表H、线性或支链(C1-C6)-烷基或CF3，R3代表H、C1-C6烷基、CO-(C1-C6)-烷基、 或CO ，R如权利要求1中所述。式(I)的甘露糖衍生物对治疗与粘附性大肠埃希菌（AEC）存在相关的病理病变有用，特别是炎症性肠病（IBD），如克罗恩病和溃疡性结肠炎；尿路感染，特别是疼痛性膀胱综合征和膀胱炎，更特别是间质性膀胱炎；肠易激综合征；代谢性疾病，如代谢性肥胖、糖尿病、高胆固醇血症；自身免疫性炎症性疾病；以及结直肠癌，特别是结肠癌。
• ARYL COMPOUNDS AS PPAR LIGANDS AND THEIR USE
  申请人：Kang Heonjoong

  公开号：US20120271055A1

  公开（公告）日：2012-10-25

  The present invention relates to a compound as a peroxisome proliferator activated receptor (PPAR) activator and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, a cosmetic composition, a muscle strengthening agent, a memory improving agent, a therapeutic agent for dementia and Parkinson's disease, a functional food and a feed composition containing the same.

  本发明涉及一种作为过氧化物酶体增殖物激活受体（PPAR）激活剂的化合物及其水合物、溶剂化合物、立体异构体和药用可接受盐，以及含有该化合物的药物组合物、化妆品组合物、肌肉强化剂、记忆改善剂、治疗痴呆症和帕金森病的药物、功能性食品和含有该化合物的饲料组合物。
• Substituted 2-(het)arylimidazolylcarboxyamides as pesticides
  申请人：Bayer CropScience Aktiengesellschaft

  公开号：US20190047982A1

  公开（公告）日：2019-02-14

  The present invention relates to compounds of the general formula (I) in which Q, V, T, W, X, Y and A have the meanings given in the description—and to their use for controlling animal pests.

  本发明涉及一般式（I）中的化合物，其中Q、V、T、W、X、Y和A具有描述中给定的含义，以及它们用于控制动物害虫的用途。
• Complementary regioselective synthesis of 3,5-disubstituted isoxazoles from ynones
  作者：Xiaochen Liu、Dongsub Hong、Zhigang She、William H. Hersh、Barney Yoo、Yu Chen

  DOI：10.1016/j.tet.2018.09.043

  日期：2018.11

  dehydration. The two routes are not only both highly regioselective, but also complementary to each other as a pair of regioisomeric 3,5-disubstituted isoxazoles are readily prepared from one single ynone substrate. The efficiency of the two routes are further evaluated and demonstrated in the synthesis of three representative 3,5-disubstituted isoxazoles.

  报道了从炔酮向3，5-二取代异恶唑的两种区域选择性合成路线。一种途径是通过首先将炔酮转化为炔酮O-甲基肟，然后进行钯催化的分子内环化而发生的。另一个涉及通过炔酮和羟胺之间的环缩合形成5-羟基-4,5-二氢异恶唑，然后进行酸介导的脱水。这两种途径不仅具有高度的区域选择性，而且彼此互补，因为可以很容易地从一个单一的炔酮底物制备一对区域异构的3,5-二取代的异恶唑。进一步评估了这两种途径的效率，并在三种代表性的3,5-二取代的异恶唑的合成中得到了证明。